

# Australia

Population 2016

24 million

| Estimates of TB burden*, 2016 | Number (thousands)  | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.048 (0.047–0.048) | 0.2 (0.2–0.2)                 |
| Mortality (HIV+TB only)       | <0.01 (<0.01–<0.01) | 0.02 (0.01–0.03)              |
| Incidence (includes HIV+TB)   | 1.5 (1.3–1.7)       | 6.1 (5.2–7.1)                 |
| Incidence (HIV+TB only)       | 0.029 (0.025–0.034) | 0.12 (0.1–0.14)               |
| Incidence (MDR/RR-TB)**       | 0.063 (0.04–0.086)  | 0.26 (0.16–0.36)              |

## Estimated TB incidence by age and sex (thousands)\*, 2016

|         | 0-14 years          | > 14 years       | Total            |
|---------|---------------------|------------------|------------------|
| Females | 0.063 (0.054–0.073) | 0.64 (0.54–0.73) | 0.7 (0.59–0.8)   |
| Males   | 0.072 (0.061–0.082) | 0.7 (0.6–0.81)   | 0.77 (0.66–0.89) |
| Total   | 0.14 (0.11–0.16)    | 1.3 (1.1–1.5)    | 1.5 (1.3–1.7)    |

## TB case notifications, 2016

|  |       |
|--|-------|
| Total cases notified                                   | 1 376 |
| Total new and relapse                                  | 1 376 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              | 83%   |
| - % pulmonary  | 63%   |
| - % bacteriologically confirmed among pulmonary        | 90%   |

## Universal health coverage and social protection

|  |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2016             | 93% (81–110)     |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.04 (0.03–0.04) |

## TB/HIV care in new and relapse TB patients, 2016

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 21     | 2%  |
| - on antiretroviral therapy                         |        |     |

| Drug-resistant TB care, 2016                                | New cases      | Previously treated cases | Total number*** |
|---|----------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                |                          | 40 (26–55)      |
| Estimated % of TB cases with MDR/RR-TB                      | 3.6% (2.2–5.4) | 24% (9.4–45)             |                 |
| % notified tested for rifampicin resistance                 | 74%            | 71%                      | 1 016           |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                |                          | 25              |
| Laboratory-confirmed cases                                  |                | MDR/RR-TB: 30, XDR-TB: 0 |                 |
| Patients started on treatment ****                          |                | MDR/RR-TB: 29, XDR-TB: 0 |                 |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2015                        | 73%     | 1 244  |
| Previously treated cases, excluding relapse, registered in 2015 |         | 0      |
| HIV-positive TB cases registered in 2015                        | 43%     | 21     |
| MDR/RR-TB cases started on second-line treatment in 2014        | 61%     | 18     |
| XDR-TB cases started on second-line treatment in 2014           | 100%    | 1      |

## TB preventive treatment, 2016

|   |
|---|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |

## TB financing, 2017

|                                    |
|------------------------------------|
| National TB budget (US\$ millions) |
|------------------------------------|

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2016



## Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB